Spots Global Cancer Trial Database for A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Official Title: A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer
Study ID: NCT01656538
Conditions
Study Description
Brief Summary: Researchers doing this study want to evaluate the side effects of Reolysin when given together with paclitaxel. As these drugs have not been given together before, 6-9 patients will be treated with paclitaxel plus reolysin to ensure that side effects are tolerable.
Detailed Description: The purpose of the randomized part of this study is to find out if giving Reolysin in combination with paclitaxel can offer better results than standard therapy with paclitaxel.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
BCCA - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Contact Details
Name: Vanessa Bernstein
Affiliation: BCCA - Vancouver Island Centre
Role: STUDY_CHAIR
Name: Susan Ellard
Affiliation: BCCA-Cancer Ctr., Southern Interior
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
